S&P 500   5,088.80
DOW   39,131.53
QQQ   436.78
Warren Buffett uses his annual letter to warn about Wall Street and recount Berkshire's successes
AI Stock Caught Trading Under Secret Name (Ad)
MarketBeat Week in Review – 2/19 - 2/23
A collection of the insights Warren Buffett offered in his annual letter Saturday
AI Stock Caught Trading Under Secret Name (Ad)
West Africa bloc lifts coup sanctions on Niger in a new push for dialogue to resolve tensions
West Africa's ECOWAS bloc says it's lifting sanctions imposed on Niger over last year’s coup in a new push for dialogue
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Macron booed by French farmers who blame him for not doing enough to support agriculture
MILAN FASHION PHOTOS: Ferragamo, Dolce&Gabbana conceal and reveal, balance transparency with cover
S&P 500   5,088.80
DOW   39,131.53
QQQ   436.78
Warren Buffett uses his annual letter to warn about Wall Street and recount Berkshire's successes
AI Stock Caught Trading Under Secret Name (Ad)
MarketBeat Week in Review – 2/19 - 2/23
A collection of the insights Warren Buffett offered in his annual letter Saturday
AI Stock Caught Trading Under Secret Name (Ad)
West Africa bloc lifts coup sanctions on Niger in a new push for dialogue to resolve tensions
West Africa's ECOWAS bloc says it's lifting sanctions imposed on Niger over last year’s coup in a new push for dialogue
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Macron booed by French farmers who blame him for not doing enough to support agriculture
MILAN FASHION PHOTOS: Ferragamo, Dolce&Gabbana conceal and reveal, balance transparency with cover
S&P 500   5,088.80
DOW   39,131.53
QQQ   436.78
Warren Buffett uses his annual letter to warn about Wall Street and recount Berkshire's successes
AI Stock Caught Trading Under Secret Name (Ad)
MarketBeat Week in Review – 2/19 - 2/23
A collection of the insights Warren Buffett offered in his annual letter Saturday
AI Stock Caught Trading Under Secret Name (Ad)
West Africa bloc lifts coup sanctions on Niger in a new push for dialogue to resolve tensions
West Africa's ECOWAS bloc says it's lifting sanctions imposed on Niger over last year’s coup in a new push for dialogue
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Macron booed by French farmers who blame him for not doing enough to support agriculture
MILAN FASHION PHOTOS: Ferragamo, Dolce&Gabbana conceal and reveal, balance transparency with cover
S&P 500   5,088.80
DOW   39,131.53
QQQ   436.78
Warren Buffett uses his annual letter to warn about Wall Street and recount Berkshire's successes
AI Stock Caught Trading Under Secret Name (Ad)
MarketBeat Week in Review – 2/19 - 2/23
A collection of the insights Warren Buffett offered in his annual letter Saturday
AI Stock Caught Trading Under Secret Name (Ad)
West Africa bloc lifts coup sanctions on Niger in a new push for dialogue to resolve tensions
West Africa's ECOWAS bloc says it's lifting sanctions imposed on Niger over last year’s coup in a new push for dialogue
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Macron booed by French farmers who blame him for not doing enough to support agriculture
MILAN FASHION PHOTOS: Ferragamo, Dolce&Gabbana conceal and reveal, balance transparency with cover
NASDAQ:GOSS

Gossamer Bio (GOSS) Stock Price, News & Analysis

$1.30
+0.14 (+12.07%)
(As of 02/23/2024 ET)
Today's Range
$1.08
$1.30
50-Day Range
$0.80
$1.30
52-Week Range
$0.45
$1.91
Volume
1.39 million shs
Average Volume
1.05 million shs
Market Capitalization
$293.03 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$4.75

Gossamer Bio MarketRank™ Stock Analysis

Analyst Rating
Hold
2.33 Rating Score
Upside/​Downside
265.4% Upside
$4.75 Price Target
Short Interest
Bearish
7.42% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-0.67
Upright™ Environmental Score
News Sentiment
0.35mentions of Gossamer Bio in the last 14 days
Based on 2 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($1.27) to ($0.79) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

3.83 out of 5 stars

Medical Sector

229th out of 942 stocks

Pharmaceutical Preparations Industry

100th out of 428 stocks


GOSS stock logo

About Gossamer Bio Stock (NASDAQ:GOSS)

Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology in the United States. The company is developing GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colonystimulating factor 1 receptor, or CSF1R, and c-KIT inhibitor for the treatment of pulmonary arterial hypertension; GB004, a gut-targeted, oral small molecule for the treatment of inflammatory bowel disease; GB5121, an oral, irreversible, covalent, small molecule inhibitor of Bruton's Tyrosine Kinase for the treatment of primary central nervous system lymphoma; and GB7208, an oral, small molecule, BTK inhibitor for the treatment of multiple sclerosis. It has license agreements with Pulmokine, Inc. to develop and commercialize GB002 and related backup compounds; and Aerpio Pharmaceuticals, Inc. to develop and commercialize GB004 and related compounds. The company was formerly known as FSG, Bio, Inc. and changed its name to Gossamer Bio, Inc. in 2017. Gossamer Bio, Inc. was incorporated in 2015 and is headquartered in San Diego, California.

GOSS Stock Price History

GOSS Stock News Headlines

Gossamer Bio Inc (GOSS)
66,000% upside on tiny biotech?
The Wall Street Journal reports that this medical breakthrough is "Transforming Medicine." One analyst calculated that it could be worth $1 Trillion, making the upside potential of this small-cap 66,000% above today's price.
7 Micro-Cap Stocks That Could Majorly Surprise Investors
Gossamer Bio Inc.
5 Small-Cap Stocks with High Potential
66,000% upside on tiny biotech?
The Wall Street Journal reports that this medical breakthrough is "Transforming Medicine." One analyst calculated that it could be worth $1 Trillion, making the upside potential of this small-cap 66,000% above today's price.
Gossamer Bio Stock (NASDAQ:GOSS) Insider Trades
COO & CFO of Gossamer Bio Picks Up 76% More Stock
Recap: Gossamer Bio Q3 Earnings
Piper Sandler Keeps Their Buy Rating on Gossamer Bio (GOSS)
See More Headlines
Receive GOSS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Gossamer Bio and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/08/2021
Today
2/25/2024
Next Earnings (Estimated)
3/15/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:GOSS
Fax
N/A
Employees
178
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$4.75
High Stock Price Target
$10.00
Low Stock Price Target
$1.25
Potential Upside/Downside
+265.4%
Consensus Rating
Hold
Rating Score (0-4)
2.33
Research Coverage
6 Analysts

Profitability

Net Income
$-229,380,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$0.13 per share

Miscellaneous

Free Float
203,995,000
Market Cap
$293.03 million
Optionable
Optionable
Beta
1.57
These 7 Stocks Will Be Magnificent in 2024 Cover

With average gains of 150% since the start of 2023, now is the time to give these stocks a look and pump up your 2024 portfolio.

Get This Free Report

Key Executives

  • Mr. Faheem Hasnain (Age 66)
    Co-Founder, CEO, President & Chairman
    Comp: $902.52k
  • Mr. Bryan  GiraudoMr. Bryan Giraudo (Age 49)
    COO & CFO
    Comp: $690.59k
  • Dr. Richard Aranda M.D. (Age 64)
    Chief Medical Officer
    Comp: $625.24k
  • Mr. Christian Waage (Age 57)
    Executive Vice President of Technical Operations & Administration
    Comp: $583.16k
  • Mr. Jeff Boerneke
    General Counsel & Secretary
  • Ms. Deanna Weber
    Senior Vice President of Human Resources
  • Mr. Mario Orlando
    Senior Vice President of Commercial New Product Planning
  • Ms. Caryn L. Peterson (Age 65)
    Executive Vice President of Regulatory Affairs
  • Mr. Matt Cravets
    Senior Vice President of Biometrics
  • Dr. Lisa Elizabeth Nolan Ph.D. (Age 62)
    MD & President of Gossamer Bio Ireland














GOSS Stock Analysis - Frequently Asked Questions

Should I buy or sell Gossamer Bio stock right now?

6 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Gossamer Bio in the last year. There are currently 4 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" GOSS shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in GOSS, but not buy additional shares or sell existing shares.
View GOSS analyst ratings
or view top-rated stocks.

What is Gossamer Bio's stock price target for 2024?

6 brokers have issued 12-month target prices for Gossamer Bio's shares. Their GOSS share price targets range from $1.25 to $10.00. On average, they anticipate the company's share price to reach $4.75 in the next twelve months. This suggests a possible upside of 265.4% from the stock's current price.
View analysts price targets for GOSS
or view top-rated stocks among Wall Street analysts.

How have GOSS shares performed in 2024?

Gossamer Bio's stock was trading at $0.9125 on January 1st, 2024. Since then, GOSS stock has increased by 42.5% and is now trading at $1.30.
View the best growth stocks for 2024 here
.

When is Gossamer Bio's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Friday, March 15th 2024.
View our GOSS earnings forecast
.

How were Gossamer Bio's earnings last quarter?

Gossamer Bio, Inc. (NASDAQ:GOSS) released its quarterly earnings results on Monday, November, 8th. The company reported ($0.80) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.78) by $0.02. During the same period in the previous year, the company earned ($0.80) EPS.

What other stocks do shareholders of Gossamer Bio own?
When did Gossamer Bio IPO?

(GOSS) raised $230 million in an IPO on Friday, February 8th 2019. The company issued 14,400,000 shares at $16.00 per share. BofA Merrill Lynch, Leerink Partners, Barclays and Evercore ISI served as the underwriters for the IPO.

Who are Gossamer Bio's major shareholders?

Gossamer Bio's stock is owned by a number of institutional and retail investors. Top institutional shareholders include Vanguard Group Inc. (5.16%), Octagon Capital Advisors LP (4.08%), Platinum Investment Management Ltd. (3.09%), Palo Alto Investors LP (2.64%), Madison Avenue Partners LP (2.24%) and Armistice Capital LLC (1.84%). Insiders that own company stock include Bryan Giraudo, Caryn Peterson, Faheem Hasnain, Laura Carter, Luisa Salter-Cid, Richard Aranda and Waage Christian.
View institutional ownership trends
.

How do I buy shares of Gossamer Bio?

Shares of GOSS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:GOSS) was last updated on 2/25/2024 by MarketBeat.com Staff